Common name
propan-1-ol
IUPAC name
propan-1-ol
SMILES
C(O)CC
Common name
propan-1-ol
IUPAC name
propan-1-ol
SMILES
C(O)CC
INCHI
InChI=1S/C3H8O/c1-2-3-4/h4H,2-3H2,1H3
FORMULA
C3H8O
Common name
propan-1-ol
IUPAC name
propan-1-ol
Molecular weight
60.095
clogP
0.038
clogS
-0.327
Frequency
0.0330
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
20.23
Number of Rings
0
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00566 | Amprenavir |
|
Anti-HIV Agents; Antibiotics, Antitubercular; Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | For the treatment of HIV-1 infection in combination with other antiretroviral agents. |
| FDBD00602 | Pentamidine |
|
Antifungal Agents; Antiprotozoal Agents; Trypanocidal Agents; Antiparasitic Products, Insecticides and Repellents; Agents Against Protozoal Diseases; Agents Against Leishmaniasis and Trypanosomiasis; Aromatic Diamidines; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For the treatment of pneumonia due to . |
| FDBD00633 | Alprostadil |
|
Platelet Aggregation Inhibitors; Vasodilator Agents; Prostaglandins; Genito Urinary System and Sex Hormones; Cardiovascular System; Drugs Used in Erectile Dysfunction; Cardiac Therapy; Urological Agents; | For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. |
| FDBD00638 | Tirofiban |
|
Fibrinolytic Agents; Platelet Aggregation Inhibitors; Antithrombotic Agents; Blood and Blood Forming Organs; Platelet Aggregation Inhibitors Excl. Heparin; | For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. |
| FDBD00648 | Marimastat |
|
Enzyme Inhibitors; | For the treatment of various cancers. |
| FDBD00669 | Proparacaine |
|
Anesthetics, Local; Ophthalmologicals; Sensory Organs; Local Anesthetics; | Used as a local (ophthalmic) anesthetic. |
| FDBD00672 | Biperiden |
|
Antiparkinson Agents; Muscarinic Antagonists; Parasympatholytics; Antidyskinetics; Nervous System; Anti-Parkinson Drugs; Anticholinergics; Tertiary Amines; CYP2D6 Inducers; CYP2D6 Inducers (strong); | For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy. |
| FDBD00712 | Pseudoephedrine |
|
Sympathomimetics; Bronchodilator Agents; Nasal Decongestants; Respiratory System; Nasal Preparations; Nasal Decongestants for Systemic Use; CYP2D6 Inducers; CYP2D6 Inducers (strong); Alpha2 Agonists; | For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism. |
| FDBD00727 | Ritodrine |
|
Sympathomimetics; Adrenergic beta-2 Receptor Agonists; Tocolytic Agents; Genito Urinary System and Sex Hormones; Sympathomimetics, Labour Repressants; Beta2 Agonists; | For the treatment and prophylaxis of premature labour. |
| FDBD00762 | Bimatoprost |
|
Antihypertensive Agents; Anti-glaucoma Agents; Ophthalmologicals; Sensory Organs; Antiglaucoma Preparations and Miotics; Prostaglandin Analogues; | For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. |
96 ,
10
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 3cow_ligand_1_0.mol2 | 3cow | 1 | -6.56 | C(C)(C)(C)CO | 6 |
| 4fhi_ligand_1_8.mol2 | 4fhi | 1 | -6.55 | C(O)C(C)(C)C | 6 |
| 4fhh_ligand_1_8.mol2 | 4fhh | 1 | -6.49 | C(O)C(C)(C)C | 6 |
| 2flh_ligand_1_0.mol2 | 2flh | 1 | -6.11 | C(O)C(C)C | 5 |
| 3bex_ligand_1_1.mol2 | 3bex | 1 | -6.04 | C(C)(C)CO | 5 |
| 3bex_ligand_1_0.mol2 | 3bex | 1 | -6.03 | C(C)(C)CO | 5 |
| 3guz_ligand_1_1.mol2 | 3guz | 1 | -6.03 | C(O)C(C)C | 5 |
| 4rce_ligand_2_5.mol2 | 4rce | 1 | -6.01 | OCC(C)(C)C | 6 |
967 ,
97
